179 related articles for article (PubMed ID: 28776394)
1. Local therapy for triple-negative breast cancer: a comprehensive review.
Grubb W; Young R; Efird J; Jindal C; Biswas T
Future Oncol; 2017 Aug; 13(19):1721-1730. PubMed ID: 28776394
[TBL] [Abstract][Full Text] [Related]
2. An overview of triple-negative breast cancer.
Kumar P; Aggarwal R
Arch Gynecol Obstet; 2016 Feb; 293(2):247-69. PubMed ID: 26341644
[TBL] [Abstract][Full Text] [Related]
3. Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer.
Asano Y; Kashiwagi S; Goto W; Kurata K; Noda S; Takashima T; Onoda N; Tanaka S; Ohsawa M; Hirakawa K
Br J Surg; 2016 Jun; 103(7):845-54. PubMed ID: 26953091
[TBL] [Abstract][Full Text] [Related]
4. Locoregional Recurrence Following Breast Cancer Surgery in the Trastuzumab Era: A Systematic Review by Subtype.
McGuire A; Lowery AJ; Kell MR; Kerin MJ; Sweeney KJ
Ann Surg Oncol; 2017 Oct; 24(11):3124-3132. PubMed ID: 28755141
[TBL] [Abstract][Full Text] [Related]
5. Where youth matters-clinicopathologic characteristics and emerging trends in treatment and outcomes in young Irish women with breast cancer.
Greally M; Kielty J; Watson GA; Das G; Malouf C; McSorley L; Coleman N; Quinn C; McDermott EW; Gullo G; Crown J; Prichard RS; Kelly CM; Walshe JM
Ir J Med Sci; 2019 Feb; 188(1):59-67. PubMed ID: 29766409
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy increases rates of breast-conserving surgery in early operable breast cancer.
Man VC; Cheung PS
Hong Kong Med J; 2017 Jun; 23(3):251-7. PubMed ID: 28484080
[TBL] [Abstract][Full Text] [Related]
7. Age, molecular subtypes and local therapy decision-making.
Kuijer A; King TA
Breast; 2017 Aug; 34 Suppl 1():S70-S77. PubMed ID: 28666919
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
9. Survival of Triple Negative versus Triple Positive Breast Cancers: Comparison and Contrast.
Negi P; Kingsley PA; Jain K; Sachdeva J; Srivastava H; Marcus S; Pannu A
Asian Pac J Cancer Prev; 2016; 17(8):3911-6. PubMed ID: 27644638
[TBL] [Abstract][Full Text] [Related]
10. Molecular Subtypes and Lower Inner Quadrant Tumors in Breast Cancer: Debate Is Still Ongoing.
Altundag K
Clin Breast Cancer; 2017 Jun; 17(3):e165. PubMed ID: 28283437
[No Abstract] [Full Text] [Related]
11. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
[TBL] [Abstract][Full Text] [Related]
12. Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?
Parker CC; Ampil F; Burton G; Li BD; Chu QD
Surgery; 2010 Aug; 148(2):386-91. PubMed ID: 20580045
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
[TBL] [Abstract][Full Text] [Related]
14. Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.
Margalit DN; Sreedhara M; Chen YH; Catalano PJ; Nguyen PL; Golshan M; Overmoyer BA; Harris JR; Brock JE
Ann Surg Oncol; 2013 Mar; 20(3):811-8. PubMed ID: 22956068
[TBL] [Abstract][Full Text] [Related]
15. Distinct outcomes in patients with different molecular subtypes of inflammatory breast cancer.
Zhou J; Yan Y; Guo L; Ou H; Hai J; Zhang C; Wu Z; Tang L
Saudi Med J; 2014 Nov; 35(11):1324-30. PubMed ID: 25399208
[TBL] [Abstract][Full Text] [Related]
16. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
17. Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation.
Panoff JE; Hurley J; Takita C; Reis IM; Zhao W; Sujoy V; Gomez CR; Jorda M; Koniaris L; Wright JL
Breast Cancer Res Treat; 2011 Aug; 128(3):899-906. PubMed ID: 21475999
[TBL] [Abstract][Full Text] [Related]
18. Management of positive margins after initial lumpectomy in elderly women with breast cancer.
Angarita FA; Acuna SA; McCready DR; Escallon J
Eur J Surg Oncol; 2018 Jul; 44(7):1048-1053. PubMed ID: 29525464
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
20. Prospective comparison of outcome after treatment for triple-negative and non-triple-negative breast cancer.
Joyce DP; Murphy D; Lowery AJ; Curran C; Barry K; Malone C; McLaughlin R; Kerin MJ
Surgeon; 2017 Oct; 15(5):272-277. PubMed ID: 28277293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
